1 USA Cancer Center, University of South Alabama, Mobile, Alabama 36688; 2 Centocor Incorporated, Malvern, Pennsylvania 19355; and 3 Department of Biochemistry and Pediatrics, State University of New York, Buffalo, New York 14214
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Separate pathways for transport of nontransferrin ferric and
ferrous iron into tissue cultured cells were demonstrated. Neither the
ferric nor ferrous pathway was shared with either zinc or copper.
Manganese shared the ferrous pathway but had no effect on cellular
uptake of ferric iron. We postulate that ferric iron was transported
into cells via 3-integrin and mobilferrin (IMP), whereas
ferrous iron uptake was facilitated by divalent metal transporter-1
(DMT-1; Nramp-2). These conclusions were documented by competitive
inhibition studies, utilization of a
3-integrin antibody
that blocked uptake of ferric but not ferrous iron, development of an
anti-DMT-1 antibody that blocked ferrous iron and manganese uptake but
not ferric iron, transfection of DMT-1 DNA into tissue culture cells
that showed enhanced uptake of ferrous iron and manganese but neither
ferric iron nor zinc, hepatic metal concentrations in mk mice showing
decreased iron and manganese but not zinc or copper, and data showing
that the addition of reducing agents to tissue culture media altered
iron binding to proteins of the IMP and DMT-1 pathways. Although these
experiments show ferric and ferrous iron can enter cells via different
pathways, they do not indicate which pathway is dominant in humans.
mobilferrin; calreticulin; integrin; divalent metal transporter-1; Nramp-2
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
ALL CELLS REQUIRE IRON TO survive (6). Iron is acquired from the diet and transported across the intestinal mucosa as either inorganic iron or heme iron. Little is known about the mechanism for transport of heme iron into the absorptive cell as a metalloporphyrin, but the transport of nonheme iron has been the object of considerable recent study. Because the lumen of the intestine does not contain adequate amounts of transferrin and the luminal surface of the enterocyte lacks transferrin receptors (34, 35), the transport of iron by intestinal cells differs from that of other cells. While nonintestinal cells are capable of transporting iron in the absence of transferrin, plasma has only low concentrations of nontransferrin bound iron, and plasma iron is mostly transported in association with transferrin. Iron is largely transported into nonintestinal nucleated cells by either of two transferrin transport mechanisms: the classical pathway utilizing the transferrin receptor and another poorly understood low-affinity system that does not utilize the classical transferrin receptor (25, 39). Recent discovery (26) of another transferrin receptor may provide insight into the low-affinity, high-capacity system. In iron-overloading disorders, ferric citrate may serve as an important contributor for delivery of iron to nonintestinal cells (24).
Despite the importance of transferrin, nonintestinal cells retain the
capability to transport inorganic iron free of transferrin (3, 7,
19, 22, 25, 32, 37, 39, 42). Tissue culture cells possess a
similar capability (15, 27, 36). In one of the best
studied cell lines, erythroleukemia-like K562 cells transport ferric
iron by the 3-integrin-mobilferrin pathway (IMP)
(15). This is the same pathway demonstrated to transport ferric iron into the intestinal mucosa of rats and humans (10, 13, 14, 17). Ferric iron is not soluble at physiological pH and
must be chelated to remain soluble above pH 3. In the intestine, the
chelator mucin is available (11), but in tissue culture systems a chelator must be added, usually citrate or nitrilotriacetic acid, to solubilize the ferric iron. The concentrations of chelators must be controlled or else the chelators both compete with cells for
iron and can cause cell damage. Ferric iron is bound to a cell surface
3-integrin (10, 16) and transferred to a
calreticulin-like chaperone protein called mobilferrin
(17). Before the iron can be used for heme synthesis it
must be converted to the ferrous valence. A cytoplasmic protein
complex, containing mobilferrin,
3-integrin, and
flavin monooxygenase as well as other peptides, uses an
electron-transport chain with energy derived from NADPH to accomplish
and maintain ferrireduction intracellularly (40, 41).
Tissue culture cells also directly transport ferrous iron, which is soluble at physiological pH but rapidly oxidized to ferric iron in an aerobic environment. A reducing agent, often ascorbic acid, must be added to maintain transiently the ferrous valence. It is believed that the ferrous pathway in nonintestinal cells is the same as in the intestine and that the iron is transported via a transmembrane pump protein, divalent metal transporter-1 (DMT-1; Nramp-2) (20, 21, 23). Although an iron-transport function has never been directly demonstrated for this protein in the intestine, the levels of the protein in enterocytes are 100-fold increased in iron deficiency (8, 38). Defects in DMT-1, expressed in the mk/mk mouse and the Belgrade rat (20, 21), result in a viable but iron-deficient animal. Once inside the cell, the ferrous iron pathway for delivery to the mitochondrion for insertion into porphyrin is not known. Iron transport into the mitochondrion was inhibited by manganese, but not by zinc, and required the ferrous valence, similar to DMT-1 (9, 29).
The IMP is unusual in that it does not involve a classical ion pump, but rather a series of interacting proteins that bind iron in vivo and in vitro. This has led some to suggest it plays no role in iron transport and that ferric iron must be reduced by an extracellular, membrane-bound ferrireductase to ferrous iron before it can be transported into the absorptive cell, presumably by the DMT-1 protein (30).
The relationship between ferric and ferrous iron-transport systems is critical for understanding the transport of inorganic iron independent of transferrin. In this study, we demonstrate that ferric iron and ferrous iron are transported by two separate pathways in K562 cells, obviating the requirement for an extracellular ferrireductase. Ferric iron does not require reduction to ferrous iron before transport. Because the pathways are believed to be the same as in the intestinal cell (15, 20), these results can be extrapolated to the in vivo situation. By utilizing tissue culture cells, it is possible to control the valence state with precision not possible in vivo.
![]() |
METHODS AND MATERIALS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Tissue culture.
K562 human erythroleukemia cells were obtained from the American Type
Culture Collection (Rockville, MD). A human kidney cell line (HEK293T)
was provided to M. D. Garrick by Dr. Mark Fleming of Children's
Hospital (Boston, MA).The K562 cells were grown in suspension in RPMI
1640 and 10% heat-inactivated fetal bovine serum (Life Technologies).
Cells were incubated in a 5% CO2 incubator (Shel-Lab,
Cornelius, OR). Cells were grown to a density of 5 × 106 cells. The cells were carefully washed in buffer free
of fetal calf serum three times (10 mM HEPES, 0.15 M NaCl, 0.1%
glucose, and 1 mM calcium and magnesium, pH 7.4). Cell viability was
judged by exclusion of 0.4% trypan blue; it always exceeded 95%
except in the presence of a high concentration of certain metals
(>104 M) when cell death and an enhanced nonspecific
binding of metals occurred. Cells were centrifuged at 1,500 rpm for 5 min to wash and concentrate cells for study (Beckman TJ6R, Palo Alto,
CA). Antibiotics were not added to tissue culture flasks to avoid
difficult-to-detect contamination (L forms) and because many
antibiotics bind iron. Approximately 1.5 × 106 cells,
monitored by using a hemocytometer, were used in each test mixture.
HEK293T cells were grown in DMEM and 10% heat-inactivated fetal bovine
serum. Media removal and washes were accomplished by pipette without
centrifugation. Otherwise, preparation was similar to that described
for K562 cells. Cells were freed from the plates by the addition of
detergent solution (1% deoxycholic acid, 1.5% Triton X-100, 0.1%
SDS, and 25 mM HEPES) for transfer to test tubes for quantification of
radioactivity in an automated gamma detector. All buffers were prepared
using doubly distilled deionized water.
Transfection of HEK293T cells. HEK293T cells were plated at 2 × 105 cells/well in six-well plastic Biocoat plates coated with poly-D-lysine (Fisher Scientific, Norcross, GA). Opti-Mem (0.5 ml) (GIBCO, Grand Island, NY) was mixed with 6 µl DMRIE (Gibco) in Falcon 2027 tubes (Becton Dickinson, San Jose, CA). One microliter of rat DMT-1 construct DNA (1 µg/ul) was mixed with 0.5 ml of Opti-Mem in Falcon 2027 tubes. The mixtures were combined and incubated for 45 min at 25°C. HEK293T cells were washed with PBS, and the mixture was added to each well and incubated for 5 h in a CO2 incubator at 37°C. Then 1.2 ml of DMEM with 20% fetal calf serum and 2 mM L-glutamine were added to each well. The cells were used for assay 48-72 h later.
Expression constructs.
Full-length rat DMT-1 wild-type and mutant (G185R) was provided by M. D. Garrick. They were subcloned into the EcoR I site p
tracer CMV 2 (Invitrogen, Carlsbad, CA). The vector contained the p
Tracer-CMV 2 promoter for high-level expression of DMT-1. The vector
also contained a human elongation factor-1 promoter for expression
of the green fluorescent protein-Zeocin fusion protein that was used to
monitor transfection efficiency. Transfection efficiencies were
obtained using fluorescence microscopy (Olympus model BX 60, Melville,
NY). The percentage of fluorescent cells was quantified visually and
showed that 25-30% of cells in our studies were transfected with
DMT-1 wild type and mutant.
Radionuclide uptake studies.
59FeCl3 (12.8 mCi/mg) or
59FeSO4 (13.4 mCi/mg),
65ZnCl2 (67.5mCi/mg), and
54MnCl2 (40 mCi/mg) were obtained from NEN
(Boston, MA). 64CuCl2 (9.3 mCi/mg) was obtained
from the University of Missouri (Columbia, MO). One milliliter of
citrate (105 M) was added to the
59FeCl3 at pH 2.2 to maintain the iron soluble
as a chelate at neutral pH when it was buffered with HEPES to pH 7.4. One milliliter of ascorbic acid (10
5 M) was added to the
59FeSO4 before dispensing it from the
manufacturer's anaerobic container. In certain experiments, the
radiolabeled ferrous ascorbate was dispensed into tissue culture cell
buffer. It contained 2-mercaptoethanol (10
4 M) to
maintain the iron in a reduced state (this concentration is commonly
employed in cultures of embryonic stem cells). Approximately 0.1 µCi
of radionuclide in 10 µl was added to 1 ml of serum-free HEPES buffer
(as described above) containing 1.5 × 106 cells. It
was incubated for 30 min at 37°C. Then the cells were washed with
three changes of a cold serum-free buffer (4°C) before the
radionuclide uptake by cells was measured in a gamma detector. In
certain experiments, nonradioactive metal salts were added in various
molaraties varying from 10
9 to 10
4 M. Higher concentrations of some metals produce cell injury as determined
by trypan blue exclusion and impaired uptake of
[14C]alanine. These cells show increased nonspecific
binding of metals to the cellular structures. In uptake experiments of
radioactive metals, carrier iron of the same redox state was added in
sufficient quantities to make the final solution 10
7 M.
Antibodies.
A monoclonal anti-3-integrin antibody (lot JG 10396) was
provided by Centocor. The antibody contained 2 mg protein/ml. The antibody was incubated with triply washed cells for 10 min at 37°C
before addition of radionuclide to the tissue culture cells. Unless
specified, 10 µl of the antibody were added to incubation mixtures
designated for antibody exposure before addition of radionuclide. A
polyclonal antibody was raised against a polypeptide sequence of human
DMT-1 (amino acids 325-339, KTNEQVVEVCTNTSS) (28). Each
rabbit was immunized with the polypeptide construct in Ribi adjuvant at
2-wk intervals for three multiple subcutaneous inoculations. Development of antibody against the polypeptide construct was monitored
in rabbit serum by an ELISA method. Preimmunization and
postimmunization serum was used for purification of IgG (Immunopure A/G
purification kit, Pierce, Rockford, IL) for use in blocking radiolabeled uptake of metals by K562 cells as described above. To test
for specificity, whole lysates of K562 cells were electrophoresed on
7.5% polyacrylamide gels and transferred to Western blots. The
purified anti-DMT-1 antibody reacted with a single band of ~58 kDa
using chemiluminescence (Amersham, Arlington Heights, IL) (Fig.
1). Chemiluminescence was quantitatively
blocked by addition of increasing amounts of the immunizing peptide to
antibody before developing the Western blot. Molecular mass was
estimated by comparison to high-range rainbow molecular weight
standards (Amersham Pharmacia Biotech, Piscataway, NJ).
|
Protein purification.
Mobilferrin, 3-integrin, and paraferritin were isolated
to near homogeneity as described previously (10, 13, 14, 16, 17,
40). DMT-1 was purified from water- insoluble, Triton X-100-insoluble fractions that were prepared as described previously to
separate DMT-1 from other iron-binding proteins in cell homogenates (10). The Triton X-100 precipitate was solubilized in 6 M
guanidine (10 mM HEPES, pH 7.4) overnight on a rotator at 4°C. The
supernatant was dialyzed against 4 M urea, which maintained the
radioiron in solution. The supernatant was used in the experiment
described in this study and contained no evidence of other known
iron-binding proteins (ELISA). DMT-1 protein was identified in this
labeled isolate by Western blot. Additional purification of DMT-1 may be accomplished by sequentially using sizing and anion-exchange columns
(ACA 22, DE-52).
Statistical analyses. Statistical analyses were performed using an unpaired t-test.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Inhibition of cellular metal uptake.
DMT-1 was reported to transport several metal cations in model systems
using frog oocytes and metallic solutions at pH 5.5 (23).
On the other hand, the IMP has been reported to be specific for ferric
iron (10, 15). In K562 cells, metals inhibited the uptake
of that metal but not most other metals tested, suggesting that metals
entered cells by different pathways (Fig.
2). Cell suspensions of K562 cells were
incubated with radiolabeled isotopes of either ferric iron, ferrous
iron, copper, zinc, or manganese. Increasing amounts of unlabeled
metals were added to the incubation mixtures to compete for the binding
site of the metals on the cell surface. After incubation at 37°C for
30 min, the cells were collected and the amount of radioactivity
incorporated into cells was determined. At ~106 M of an
unlabeled metal, the uptake of that metal was 50% decreased, reflecting the binding coefficient of the cell transporter for that
metal. The unlabeled metal attached to a specific metal binding site
decreased the uptake of label. Ferrous iron, ferric iron, zinc, and
copper did not inhibit the uptake of each other, indicating they were
taken up by different cellular pathways (Fig. 2, A, B, and C). The ability of manganese to decrease
ferrous iron uptake indicated that both metals compete for the same
cellular transporter (9). On the other hand, manganese
exerted no effect on the uptake of ferric iron (Fig. 2D),
showing that ferric iron was capable of being transported into cells by
a different pathway than either ferrous iron or manganese. It also
suggested that manganese may be a useful surrogate for ferrous iron in
transport experiments; manganese is soluble at physiological pH, does
not require reducing agents to maintain its redox state, and appears to
be less toxic than most other metals tested at high concentrations (>10
4 M).
|
Blocking 3-integrin antibody.
A monoclonal anti-
3-integrin antibody was raised (lot JG
10396, Centocor) that blocked 59Fe3+ citrate
uptake in K562 erythroleukemia cells (Fig.
3). The antibody produced no inhibition
of iron uptake from solutions containing ferrous iron maintained in the
appropriate valence by ascorbate and 2-mercaptoethanol. The lack of
inhibition by Tiron, an impermeable ferric iron chelator (1, 2,
5), indicated that the iron remained in the ferrous valance and
that Tiron did not have a nonspecific toxic effect on the cells. This
was in marked contrast to the effect of anti-
3-integrin
antibody on uptake of ferric iron (as the citrate chelate). Ferric iron
uptake by cells was virtually abolished by the antibody. Ferric uptake
was also inhibited by Tiron as expected. The decrease in ferric iron
uptake produced by anti-
3-integrin antibody in both K562
erythroleukemia cells was dependent on the quantity of antibody
incubated with the cells before the addition of a radiolabeled
ferric citrate (Fig. 4). The
anti-
3-integrin antibody did not inhibit the cellular
uptake of 65Zn probably because zinc utilizes a
1-integrin to enter cells (15). Other
antibodies (see below) had no blocking effect. Trypan blue exclusion in
96% of cells after incubation with antibody and radioiron indicated
that no nonspecific toxicity to the cells was present. The differential
effect of the antibody implied that at least one element in the ferric
pathway was not shared by the ferrous pathway.
|
|
Blocking DMT-1 antibody.
A purified polyclonal antibody was developed against a peptide sequence
from human DMT-1 (KTNEQVVEVCTNTSS) (28). The antibody was
shown to inhibit quantitatively the uptake of ferrous iron from a dose
of ferrous sulfate (59FeSO4; ascorbic acid,
106 M; 2-mercaptoethanol, 10
4 M) and
54MnCl2 (Fig. 5).
Increasing amounts of antibody showed increasing ability to block the
intracellular uptake of ferrous iron and manganese. Preimmune sera had
no effect. These data were consistent with the inhibition of ferrous
iron uptake by manganese in a shared divalent cation pathway (Fig.
2D). The antibody did not inhibit the cellular uptake of
59ferric citrate even at concentrations resulting in >80%
inhibition of ferrous uptake. In similar experiments, the anti-DMT-1
antibody did not inhibit uptake of divalent 65zinc. The
polyclonal antibody was highly selective for DMT-1 because the antibody
only showed activity against DMT-1 isoforms on Western blots. Even if
the specificity was broader than demonstrated by Western analysis and
included some activity against an otherwise unknown transport system,
the antibody still clearly differentiated ferrous from ferric iron
transport, providing convincing evidence for separate pathways.
|
Transfection of DMT-1 DNA into HEK-T cells.
Further evidence that the ferrous transport system in tissue culture
cells involved the DMT-1 system and that this was a separate pathway
from ferric iron transport was obtained by use of transient overexpression of the DMT-1 protein in HEK293T cells (Fig.
6). The transfection of DMT-1 DNA wild
type into HEK293T kidney cells showed an ~30% increase in uptake of
ferrous iron and manganese compared with wild-type cells. Untransfected
cells or cells receiving mutant DMT-1 DNA (Belgrade rat, G185R) failed
to demonstrate an increase. In both cases ~20-30% of the cell
population contained the plasmid as demonstrated by green fluorescent
protein. The transfection of DMT-1 DNA had no effect on the uptake of
ferric iron or zinc.
|
Metal concentrations in liver specimens from mk/mk and
+ /mk mice.
Specimens of liver were obtained from homozygous (mk/mk)and
heterozygous (+/mk) mice at autopsy. Aliquots were oven dried and
weighed. Metals were extracted with TCA to precipitate heme and protein
and avoid heme iron in the assay. The metal concentration in the
extracts was measured in an atomic absorption spectrometer. The iron
and manganese concentrations were significantly decreased in specimens
from homozygous mice. The concentrations of both zinc and copper were
similar in the livers of homozygous and heterozygous animals. These
data indicate that the mutation in the mk mouse significantly affected
acquisition of both iron and manganese but had little effect on the
uptake and retention of zinc and copper (Table
1).
|
Iron-uptake pathways are altered in a reducing environment.
Biochemical methods for isolating the iron-binding proteins of the IMP
were described previously (10, 12-17, 39). DMT-1 was
isolated to near homogeneity (Fig. 7). It
was water and Triton X-100 insoluble but solubilized in 6 M guanidine
from the Triton X-100- insoluble residue. The product of this isolation
contained a 58-kDa band that was identified as DMT-1 by the specific
antibody and chemiluminescence on a Western blot similar to Fig. 1.
After a 10-min incubation of 59Fe3+ citrate
with K562 cells in the absence of reducing agents, the radioiron was
recovered predominantly in proteins of the IMP. However, when the cells
were pretreated with 2-mercaptoethanol most of the recovered radioiron
was found in association with DMT-1. This indicates that both pathways
were operative simultaneously under the two conditions of the
experiment but that the quantity of ferric iron that becomes available
to the DMT-1 pathway is increased with ferrireduction. The binding of
small quantities of radioiron to DMT-1 in K562 cells in the absence of
2-mercaptoethanol could be the result of either extracellular
ferrireductase activity or intercourse between the IMP and DMT-1
pathways or both. However, most of the recovered radioiron was bound to
proteins of the IMP in the absence of 2-mercaptoethanol.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Iron is vital for all living organisms because it is essential for multiple metabolic processes including oxygen transport, DNA synthesis, and electron transport (6). Iron homeostasis is accomplished in mammals largely by regulating absorption in the proximal small intestine. Iron excretion is limited and plays a more passive role. Absorption of iron as ferrous, ferric, and heme iron balances body losses of iron. Consistent failure to maintain this equilibrium results in either iron deficiency or siderosis. Nonintestinal cells acquire most of their iron from plasma transferrin, utilizing either the classical transferrin-transferrin receptor pathway or the transferrin receptor independent pathway (25). All nucleated cells tested also possessed the capability to transport iron independent of transferrin (3, 7, 15, 19, 30, 33, 39, 42). The physiological role of these pathways in nonintestinal cells is unclear in the absence of iron-overloaded states. The pathways for inorganic iron transport independent of transferrin into nucleated nonintestinal cells have been shown to be the same as used by intestinal cells (15). The relationship between inorganic ferrous and ferric iron transport has been unclear. The data in this communication indicate that cellular uptake of ferric and ferrous iron occurs via different pathways. Current data suggest that ferric iron utilizes the IMP whereas ferrous iron uses the DMT-1 pathway.
The existence of two pathways was shown by a combination of biochemical, immunologic, and genetic methods. Each method demonstrated two separate pathways. Biochemically, manganese inhibited the uptake of ferrous but not ferric iron. It is conceivable that ferrous iron could be catalytically oxidized to ferric iron before transport and that this step was inhibited by manganese. However, the ferric chelator Tiron inhibited ferric uptake, but not ferrous, so that this mechanism is not probable. Ferric iron was not converted to ferrous iron before transport, because in that case ferric iron uptake would have been inhibited by manganese, which was not observed.
Immunologically distinct antibodies to key elements in the separate
pathways inhibited specific pathways, but no antibody inhibited both
pathways. The antibody to the integrin involved in the IMP inhibited
ferric transport but not ferrous uptake. The antibody to DMT-1
inhibited ferrous transport but had no effect on ferric uptake by the
cell. Because neither antibody inhibited uptake of both ferric and
ferrous iron, there must be specific elements unique to each pathway
making the pathways distinct. The lack of inhibition of ferric iron
uptake with anti-DMT-1 and ferrous iron with
anti-3-integrin excludes nonspecific iron binding to
cells as a significant variable in these studies.
Genetic methods showed that overexpression of the DMT-1 pathway did not increase ferric transport. However, it increased both ferrous iron and manganese uptake.
Individualized absorptive pathways for nutritional metals protect against deficiencies of other vital metals by not competing for the same transport pathway to enter the enterocyte. For example, the divalent cation zinc appeared to be transported by a pathway unshared with either ferrous or ferric iron. Separate pathways for zinc and iron would prevent zinc deficiency in mammals on an iron-replete diet (15). A shared pathway for ferrous iron and manganese would be less important because most dietary iron is ferric iron.
The relative physiological roles in the absorption of iron by the two nonheme iron uptake pathways, the IMP and the DMT-1, are not known. The following information is available. 1) DMT-1 missense mutations were associated with a disease in rodents (mk mouse and Belgrade rat) (20, 21), and the calreticulin/mobilferrin knockout mouse has not been viable (18, 31). 2) The DMT-1 protein was dramatically increased in intestinal cells in severe iron deficiency in mice (8), and the activity of the IMP was increased in iron-deficient rats (12). 3) The DMT-1 protein was immunologically undetectable in the microvilli of freshly obtained normal human duodenum at Whipple surgery (unpublished data) and in the duodenum of normal rodents (8), and the mobilferrin-integrin pathway was active in normal human duodenum (14). 4) The DMT-1 protein appeared to transport some nonferrous metals of nutritional importance, whereas the IMP was specific for import of ferric iron into the cell (23). 5) Lastly, a defect in the IMP was identified in a family with sideroblastic anemia, a genetic disorder with iron overloading (4).
![]() |
ACKNOWLEDGEMENTS |
---|
This study was supported by National Institute of Diabetes and Digestive and Kidney Diseases Merit Award 2R37 DK-36112 and National Heart, Lung, and Blood Institute 2R01 HL-48690.
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: M. E. Conrad, USA Cancer Center, Univ. of South Alabama, Mobile, AL 36688 (E-mail: mconrad{at}usamail.usouthal.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 4 January 2000; accepted in final form 1 May 2000.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Alcain, FJ,
Low H,
and
Crane FL.
Inhibition of DNA synthesis in CCl 39 cells by impermeable iron chelators.
Biochem Mol Biol Int
41:
303-310,
1997[ISI][Medline].
2.
Alcain, FJ,
Low H,
and
Crane FL.
Iron at the cell surface controls DNA synthesis in CCl 39 cells.
Biochem Biophys Res Commun
203:
16-21,
1994[ISI][Medline].
3.
Baker, E,
Baker SM,
and
Morgan EH.
Characterization of nontransferrin-bound iron (ferric citrate) uptake by rat hepatocytes in culture.
Biochim Biophys Acta
380:
21-30,
1998.
4.
Barber M, Conrad ME, Umbreit JN, Barton JC, and Moore EG.
Abnormalities of flavin monooxygenase as an etiology for sideroblastic
anemia. Am J Hematol. In press.
5.
Berger, SA,
and
McKay JB
The photometric titration of Fe(III) with EDTA using Tiron indicator.
Mikrochim Acta
4:
665-670,
1974[Medline].
6.
Bothwell, TH,
Charlton RW,
Cook JD,
and
Finch CA.
Iron Metabolism in Man. Oxford: Blackwell Scientific, 1979, p. 7-81.
7.
Brissot, P,
Wright TL,
Ma WL,
and
Weisiger RA.
Efficient clearance of nontransferrin-bound iron by rat liver. Implications for hepatic iron loading in iron-overload states.
J Clin Invest
76:
1463-1470,
1985[ISI][Medline].
8.
Canonne-Hergaux, F,
Gruenheid S,
Ponka P,
and
Gros P.
Cellular and subcellular localizations of the Nramp2 iron transporter in the intestinal brush border and regulation by dietary iron.
Blood
93:
4406-4417,
1999
9.
Chua, AC,
and
Morgan EH.
Manganese metabolism is impaired in the Belgrade laboratory rat.
J Comp Physiol [B]
167:
361-369,
1997[ISI][Medline].
10.
Conrad, ME,
and
Umbreit JN.
Iron absorption: the mucin-mobilferrin-integrin pathway. A competitive pathway for metal absorption.
Am J Hematol
42:
67-73,
1993[ISI][Medline].
11.
Conrad, ME,
Umbreit JN,
and
Moore EG.
A role for mucin in the absorption of inorganic iron and other metal cations. A study in rats.
Gastroenterology
100:
129-136,
1991[ISI][Medline].
12.
Conrad, ME,
Umbreit JN,
and
Moore EG.
Regulation of iron absorption proteins involved in duodenal mucosal uptake and transport.
J Am Coll Nutr
12:
720-728,
1993[Abstract].
13.
Conrad, ME,
Umbreit JN,
and
Moore EG.
Rat duodenal iron-binding protein mobilferrin is a homologue of calreticulin.
Gastroenterology
104:
1700-1704,
1993[ISI][Medline].
14.
Conrad, ME,
Umbreit JN,
Moore EG,
and
Rodning CR.
Newly identified iron binding protein in human duodenal mucosa.
Blood
79:
244-247,
1992[Abstract].
15.
Conrad, ME,
Umbreit JN,
Moore EG,
Uzel C,
and
Berry MR.
The alternate iron transport pathway. Mobilferrin and integrin in K562 cells.
J Biol Chem
269:
7169-7173,
1994
16.
Conrad, ME,
Umbreit JN,
and
Peterson RDA
Function of integrin in duodenal mucosal uptake of iron.
Blood
81:
517-521,
1993[Abstract].
17.
Conrad, ME,
Umbreit JN,
Peterson RDA,
Moore EG,
and
Jones M.
A newly identified iron binding protein in duodenal mucosa of rats. Purification and characterization of mobilferrin.
J Biol Chem
265:
5273-5279,
1990
18.
Coppolino, MG,
Woodside MJ,
Demaurex N,
Grinstein S,
St-Arnaud R,
and
Dedhar S.
Calreticulin is essential for integrin-mediated calcium signaling and cell adhesion.
Nature
386:
843-847,
1997[ISI][Medline].
19.
Egyed, A.
Carrier mediated iron transport through erythroid cell membrane.
Br J Haematol
68:
483-486,
1988[ISI][Medline].
20.
Fleming, MD,
Romano MA,
Su MA,
Garrick MD,
and
Andrews NC.
Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport.
Proc Natl Acad Sci USA
95:
1148-1153,
1998
21.
Fleming, MD,
Trevor CC,
Su MA,
Foernzler D,
Beier DR,
Dietrich WF,
and
Andrews NC.
Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene.
Nat Genet
4:
383-386,
1997.
22.
Graham, RM,
Morgan EH,
and
Baker E.
Characterisation of citrate and iron citrate uptake by cultured rat hepatocytes.
J Hepatol
4:
603-613,
1998.
23.
Gunshin, H,
Mackenzie B,
Berger UV,
Gunshin Y,
Romero MF,
Boron WF,
and
Nussberger S.
Cloning and characterization of a mammalian proton-coupled metal-ion transporter.
Nature
388:
482-488,
1997[ISI][Medline].
24.
Gutierez, JA,
and
Wessling-Resnick M.
Molecular mechanisms of iron transport.
Crit Rev Eukaryot Gene Expr
6:
41-46,
1996.
25.
Hodgson, LL,
Quail EA,
and
Morgan EH.
Iron transport mechanisms in reticulocytes and mature erythrocytes.
J Cell Physiol
162:
181-190,
1995[ISI][Medline].
26.
Kaeabata, H,
Yang R,
Hirama T,
Vuong PT,
Kawano S,
Gombart AE,
and
Koeffler HP.
Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor like family.
J Biol Chem
274:
20820-20826,
1999.
27.
Kaplan, J,
Jordan I,
and
Sturrock A.
Regulation of the transferrin-independent iron transport system in cultured cells.
J Biol Chem
266:
2997-3004,
1991
28.
Kishi, F,
and
Tabuchi M.
Complete nucleotide sequence of human Nramp2 cDNA.
Mol Immunol
34:
839-842,
1997[ISI][Medline].
29.
Lange, H,
Kispal G,
and
Lill R.
Mechanism of iron transport to the site of heme synthesis inside yeast mitochondria.
J Biol Chem
274:
18489-18496,
1999.
30.
May, JM.
Is ascorbic acid an antioxidant for the plasma membrane?
FASEB J
13:
995-1006,
1999
31.
Mesaeli, N,
Nakamura K,
Zvaritch E,
Dickie P,
Dziak E,
Krause KH,
Opas M,
MacLennan DH,
and
Michalak M.
Calreticulin is essential for cardiac development.
J Cell Biol
144:
857-868,
1999
32.
Morgan, EH.
Membrane transport of nontransferrin-bound iron by reticulocytes.
Biochim Biophys Acta
943:
428-439,
1988[ISI][Medline].
33.
Nunez Escobar, A MT,
Ahumada A,
and
Gonzalez-Sepulveda M.
Sealed reticulocyte ghosts. An experimental model for the study of Fe2+ transport.
J Biol Chem
267:
11490-11494,
1992
34.
Parmley, RT,
Barton JC,
and
Conrad ME.
Ultrastructural localization of transferrin, transferrin receptor and iron binding sites on human placenta and duodenal microvilli.
Br J Haematol
60:
81-89,
1985[ISI][Medline].
35.
Pietrangelo, A,
Rocchi E,
Casagrandi G,
Rigo G,
Ferrari A,
Perini M,
Ventura E,
and
Cairo G.
Regulation of transferrin, transferrin receptor and ferritin genes in human duodenum.
Gastroenterology
102:
802-809,
1992[ISI][Medline].
36.
Seligman, PA,
Kovar J,
Schleicher RB,
and
Gelfand EW.
Transferrin-independent iron uptake supports B lymphocyte growth.
Blood
78:
1526-1531,
1991[Abstract].
37.
Sturrock, A,
Alexander J,
Lamb J,
Craven CM,
and
Kaplan J.
Characterization of a transferrin-independent uptake system for iron in HeLa cells.
J Biol Chem
265:
3139-3145,
1990
38.
Tandy, S,
Williams M,
Leggett A,
Lopez-Jiminez M,
Dedes M,
Ranesh B,
Srai SK,
and
Sharp P.
Nramp2 expression is associated with pH dependent iron uptake across the apical membrane of human intestinal CaCo cells.
J Biol Chem
275:
1023-1029,
2000
39.
Trinder, D,
and
Morgan E.
Inhibition of uptake of transferrin-bound iron by human hepatoma cells by nontransferrin bound iron.
Hepatology
26:
691-698,
1997[ISI][Medline].
40.
Umbreit, JN,
Conrad ME,
Moore EG,
Desai MP,
and
Turrens J.
Paraferritin: a protein complex with flavin monooxygenase activity is associated with iron absorption in rats.
Biochemistry
35:
6460-6469,
1996[ISI][Medline].
41.
Umbreit, JN,
Conrad ME,
Moore EG,
and
Latour LF.
Iron absorption and cellular transport: the mobilferrin/paraferritin paradigm.
Semin Hematol
35:
13-26,
1998[ISI][Medline].
42.
Wright, TL,
Fitz JG,
and
Weisiger RA.
Nontransferrin-bound iron uptake by rat liver. Role of membrane potential differences.
J Biol Chem
263:
1842-1847,
1988